Advertisement
U.S. Markets closed

Innovent Biologics, Inc. (IVBXF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed Price. Currency in USD
5.900.00 (0.00%)
At close: 04:00PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 9.73B
Enterprise Value 9.02B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)9.03
Price/Book (mrq)5.51
Enterprise Value/Revenue 8.61
Enterprise Value/EBITDA -6.45

Trading Information

Stock Price History

Beta (5Y Monthly) 0.12
52-Week Change 3N/A
S&P500 52-Week Change 3N/A
52 Week High 36.41
52 Week Low 33.83
50-Day Moving Average 35.66
200-Day Moving Average 35.06

Share Statistics

Avg Vol (3 month) 38.92k
Avg Vol (10 day) 321.9k
Shares Outstanding 51.63B
Implied Shares Outstanding 6N/A
Float 81.42B
% Held by Insiders 16.79%
% Held by Institutions 147.47%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 3�
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in CNY.

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Jun 30, 2024

Profitability

Profit Margin -17.18%
Operating Margin (ttm)-10.94%

Management Effectiveness

Return on Assets (ttm)-4.18%
Return on Equity (ttm)-11.04%

Income Statement

Revenue (ttm)7.46B
Revenue Per Share (ttm)4.65
Quarterly Revenue Growth (yoy)46.30%
Gross Profit (ttm)N/A
EBITDA -990.62M
Net Income Avi to Common (ttm)-1.28B
Diluted EPS (ttm)-0.11
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)8.63B
Total Cash Per Share (mrq)5.3
Total Debt (mrq)3.35B
Total Debt/Equity (mrq)26.95
Current Ratio (mrq)2.68
Book Value Per Share (mrq)7.63

Cash Flow Statement

Operating Cash Flow (ttm)555.07M
Levered Free Cash Flow (ttm)-176.4M